From Faulding to Mayne Pharma
The history of Mayne Pharma is intricate and began with FH Faulding & Co Ltd.
From 1845 until 2001, Mayne Pharma was known as FH Faulding & Co where amongst other activities including pharmaceutical wholesaling and consumer health products, it built success around optimizing the delivery of oral dosage form drugs.
In 2001, Mayne Group Ltd acquired FH Faulding & Co and then in November 2005, Mayne Group Ltd demerged the business into:
- Mayne Pharma Limited; a global pharmaceutical company focused on research and development, manufacture, marketing and distribution of injectable and oral pharmaceuticals; and
- Symbion Health Limited – a large Australian healthcare-focused company with leading market positions in pathology, diagnostic imaging, pharmacy and health-related consumer products.
In February 2007, Hospira Inc announced that it had completed the acquisition of Mayne Pharma Limited as it tied in with the firm’s skills in specialty generic injectable pharmaceuticals.
In October 2009, the oral pharmaceutical division of Mayne Pharma Limited was purchased from Hospira Inc by Halcygen Pharmaceuticals Ltd.
In November 2010, Halcygen Pharmaceuticals Ltd changed its name to Mayne Pharma Group Limited, which is listed on the Australian Securities Exchange under the ASX code “MYX”.